The EU Clinical Trials Regulation (CTR) represented a significant shift in the regulatory landscape, aiming to create a more favourable environment for clinical research across Europe. ICON has adeptly adapted to these new regulations, leveraging our Netherlands efficiencies model to streamline submissions and ensure rapid turnaround times.
ICON’s current experience to date includes 47 submissions, with 40 approved. The one-round request for information (RFI) average stands at 40.2 days, with a minimum of 35 days and a maximum of 46 days. This demonstrates ICON’s ability to efficiently navigate the submission process, minimising delays, and maximising approval timelines.
![blog-graphic blog-graphic](https://icon.widen.net/content/ux7ukimvnl/web/blog-graphic.jpg)
Understanding the EU CTR
The EU CTR replaces the previous Directive 2001/20/EC, introducing several key changes to the clinical trial submission process. These include a single submission portal and a coordinated assessment procedure, designed to streamline the process, reduce duplication, and enhance the quality of clinical trials conducted across Europe. While these changes bring numerous benefits, they also require sponsors to adjust to new procedures and timelines.
To ensure a swift and efficient submission process under the EU CTR, ICON has implemented several key strategies. Immediate responsiveness is achieved by notifying the Institutional Ethics Committee (IEC) via email, ensuring preapproval of advertising materials sent in advance. The validation process features a quick turnaround, with rapid follow-up upon receiving responses to expedite validation. IEC meetings are scheduled timely to facilitate quick site activation post-award, with advertising conducted prior to package approval. Prompt responses to requests for information (RFIs) are crucial for maintaining the momentum of the submission process. Upon receipt of the letter of approval, the greenlight procedure can be performed, allowing screening to commence immediately after the site initiation visit.
Lessons learned - early phase
Based on our extensive experience, ICON has identified several key areas to focus on to ensure a smooth submission process and maximise approval timelines. Early determination of requirements and roles for OMS registration, along with reviewing expectations and requirements in advance, is critical. Applying for the EU CT number early in the study start-up phase helps avoid delays.
XEVMPD registration of the investigational medicinal product (IMP) is necessary for both the drug substance and product for IMPD submission. Deciding whether a single country or single site approach is most appropriate and choosing the Reporting Member State (RMS) and local IEC accordingly is essential. Prioritising study team activities ensures a fast turnaround of responses and document updates.
Additionally, maintaining open communication and meeting planned timelines through effective collaboration and clear expectations are vital. Regularly consulting EMA guidance documents and asking questions helps stay informed and prepared. Conducting a thorough review of the scope and resourcing of services ensures alignment with project goals and helps avoid changes.
ICON's commitment to excellence
ICON’s strategic approach and dedicated processes ensure that we can leverage the opportunities presented by the EU CTR while adhering to our legal responsibilities. By focusing on efficient communication, thorough planning, and prompt responses, we are able to streamline the submission process and achieve fast turnaround times. This commitment to excellence not only benefits our clients but also contributes to the advancement of clinical research in Europe.
In conclusion, ICON’s experience and strategic approach to the EU CTR submission process highlights our ability to navigate regulatory changes effectively. By implementing efficient procedures and maintaining open communication, we ensure that submissions are timely and meet the high standards required by regulatory authorities. Our track record of successful submissions and quick turnaround times demonstrates our capability to support sponsors in achieving their clinical research goals under the new regulatory framework.
If you would like to discover how ICON can assist you with your early phase clinical trials, then please visit ICONplc.com/earlyphase
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Flexible delivery models
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel